COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.

Oechsner, M

COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. [electronic resource] - Journal of neural transmission (Vienna, Austria : 1996) 2002 - 69-75 p. digital

Publication Type: Journal Article

0300-9564

10.1007/s702-002-8237-z doi


3,4-Dihydroxyphenylacetic Acid--blood
Aged
Aged, 80 and over
Antiparkinson Agents--therapeutic use
Benzophenones--therapeutic use
Catechol O-Methyltransferase Inhibitors
Dihydroxyphenylalanine--analogs & derivatives
Disease Progression
Dose-Response Relationship, Drug
Female
Homovanillic Acid--blood
Humans
Levodopa--administration & dosage
Male
Middle Aged
Nitrophenols
Parkinson Disease--blood
Tolcapone
Tyrosine--analogs & derivatives